Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...

Merck (MRK) reported fourth quarter and full-year earnings Tuesday, in line with Wall Street estimates. The bad news: Its stock was down more than 10% in early trading, largely because of weaker ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.